Note 2 - Liquidity	3 Months Ended
Mar. 31, 2017
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 - LIQUIDITY We continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of $657,853 and $739,785 for the three months ended March 31, 2017 and 2016, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $9,239,976 as of March 31, 2017. The Company anticipates further losses in the development of its business. The Company had a net working capital of $2,176,353 at March 31, 2017. Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the third quarter of 2018. Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the third quarter of 2018.

NOTE

- LIQUIDITY

We continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of

$657,853

and

$739,785

for the

three

months ended

March

31,

2017

and

2016,

respectively. The Company has incurred losses since inception resulting in an accumulated deficit of

$9,239,976

as of

March

31,

2017.

The Company anticipates further losses in the development of its business. The Company had a net working capital of

$2,176,353

March

31,

2017.

Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the

third

quarter of

2018.

Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the

third

quarter of

2018.